Physician profile
Ryan M Dunn
NPI 1144538083
$1,594.83
in general payments reported to CMS, 2019-2025
21 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $244 · 2023: $359 · 2024: $445 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $208.35 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $191.52 | 2021-2025 | Repatha, Repatha |
| Abiomed | $156.44 | 2024-2025 | Impella |
| Irhythm Technologies, INC. | $150.50 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $139.11 | 2021-2024 | Xarelto |
| Pfizer INC. | $111.94 | 2021-2025 | |
| Esperion Therapeutics, INC. | $96.58 | 2023-2025 | Nexletol |
| Heartflow, INC. | $87.96 | 2024 | |
| Novo Nordisk INC | $77.41 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $60.08 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.34 | 2021-2022 | |
| Cvrx, INC. | $39.94 | 2022 | |
| Scpharmaceuticals INC. | $32.94 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.22 | 2022-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $29.82 | 2022-2023 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.45 | 2025 | |
| Daiichi Sankyo INC. | $27.46 | 2023 | Injectafer |
| Agepha Pharma Fz LLC | $24.27 | 2025 | Lodoco |
| Abbott Laboratories | $20.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.53 | 2021 | |
| Lilly USA, LLC | $15.65 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.